KANCERA AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.722 SEK | +17.14% |
|
+13.14% | -62.11% |
| 08/05 | Kancera AB Announces Executive Changes | CI |
| 03/05 | Kancera AB Reports Positive Results from the Clinical Phase I Study with KAND145 in Healthy Subjects | CI |
Summary
- According to Refinitiv, the company's ESG score for its industry is poor.
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Sales forecast by analysts have been recently revised upwards.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company has insufficient levels of profitability.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -62.11% | 16.4M | D | ||
| +3.92% | 108B | B+ | ||
| +11.29% | 104B | B+ | ||
| +1.28% | 22.33B | B | ||
| -12.98% | 22.19B | B+ | ||
| -7.05% | 18.69B | A- | ||
| -38.36% | 17.74B | A- | ||
| -9.76% | 17.64B | B | ||
| +3.67% | 14.05B | C+ | ||
| +35.92% | 12.51B | C+ |
Investor Rating
Trading Rating
-
ESG Refinitiv
Financials
Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
-
Valuation
P/E ratio
-
EV / Sales
-
Price to Book
-
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
-
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- KAN Stock
- Ratings Kancera AB